The Ministry of Health, Labour and Welfare (MHLW) in Japan has cleared Ezharmia (valemetostat tosylate) based on the results of an open-label phase 2 trial which revealed a 48% overall response rate with the drug in previously-treated ATL patients.
ATL is a rare and highly aggressive form of non-Hodgkin lymphoma (NHL), generally associated with infection by the HTLV-1 retrovirus, that can manifest as either a lymphoma or a leukaemia. It is usually treated with chemotherapy, but has a high rate of relapse and a low five-year survival rate of between 12% and 14%.
